Ldl Cholesterol
Statins
Primary Prevention- No Diabetes and LDL-C <190 mg/dL
Primary Prevention- LDL-C ≥190 mg/dL
2018 ACC/AHA Multi-Society Cholesterol Guideline Overview
Body fat, metabolic changes before pancreatic cancer diagnosis may aid in early detection
In the 36 months prior to diagnosis of pancreatic ductal adenocarcinoma, researchers observed “predominant changes” in patients’ body composition and biochemical markers, which may serve as potential biomarkers for early cancer detection.
In chronic coronary syndrome, women less likely to get cholesterol-lowering drugs vs. men
Among patients with chronic coronary syndrome, women were less likely than men to be treated with lipid-lowering therapy, researchers reported at ESC Preventive Cardiology 2024.
VIDEO: PCSK9 inhibitor lerodalcibep shows LDL cholesterol reduction
ATLANTA — In this Healio video exclusive, Erica S. Spatz, MD, MHS, discusses research into lipid disorders from the American College of Cardiology Scientific Session, examining results of the LIBerate-HR trial on LDL cholesterol levels.
Monthly PCSK9 inhibitor cuts cholesterol by half on top of statin, ezetimibe therapy
ATLANTA — An investigational monthly PCSK9 inhibitor cut LDL cholesterol by more than 50% at 1 year among adults with CVD or with very high risk, in addition to background statin and ezetimibe therapy, researchers reported.
Web app can help patients determine if they qualify for a statin without a prescription
ATLANTA — New results from the TACTiC trial show the promise of technology to help individuals appropriately determine if they qualify for statin therapy without a prescription.
‘Inclisiran-first’ strategy yields greater LDL reductions vs. usual care for patients with CVD
ATLANTA — For patients with atherosclerotic CVD, an inclisiran-first strategy was associated with greater lowering of LDL compared with the usual care, researchers reported at the American College of Cardiology Scientific Session.